ClinicalTrials.gg
RecruitingNCT05732701TAILOR-DAPTUpdated Nov 3, 2026

Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions

An interventional study of Algorithm-guided DAPT duration and Standard-of-care DAPT duration in Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors and Coronary Artery Disease, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.
Updated Nov 3, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,788
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Insel Gruppe AG, University Hospital Bern.

Planned enrollment
Largest of 23
2,788 · median 100
Started
2023
the only one that year
No phase
18 of 34
4 open now
Registered
32nd of 34
by date

Among the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, this one has the largest planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2023, is one of 18 with no phase, and was the 32nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.

Read the detailed description

Background:

The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. European guidelines recommend to implement risk scores to guide the duration of DAPT after stent implantation (class IIb, level of evidence A). However, its adoption rate remains exceedingly low in daily clinical practice in part due to the lack of direct evidence obtained from a randomized controlled trial supporting this strategy.

Aim:

Using a pragmatic study-design, the investigators aim to determine the efficacy and safety of an algorithm-guided strategy for DAPT duration compared to a standard-of-care DAPT without the use of risk scores in patients undergoing PCI with stent implantation.

Methodology:

This investigator-initiated, single-blind, randomized trial will include a total of 2788 patients aged ≥18 years undergoing PCI with stent implantation. Main exclusion criteria are peri-procedural complications potentially affecting DAPT duration. The study will be nested into a well-running registry to minimize study-related costs (pragmatic trial approach). Patients will be randomized to an algorithm-guided DAPT group or a standard-of-care DAPT group in a 1:1 fashion. In the algorithm-guided group, DAPT duration will be determined according to the PRECISE-DAPT score (≥25 or \<25) / Precise-HBR score (≥23 or \<23), PCI complexity, and clinical presentation (acute or chronic coronary syndromes). In the standard-of-care DAPT group, treatment duration is at the operator's discretion. The primary endpoint is a composite of net adverse clinical events (NACE) defined as all-cause death, spontaneous myocardial infarction, stroke, definite stent thrombosis or Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding at 1 year.

Potential significance:

This will be the first study evaluating the impact of a score-based decision-making algorithm integrating bleeding and ischemic risks for DAPT duration among patients undergoing PCI. The hypothesis is that the proposed simple decision-making algorithm minimizes bleeding risk and maximizes ischemic benefit compared to a standard-of-care DAPT regimen. Prospective data obtained from a pragmatic randomized controlled trial embedded into an on-going, well-managed PCI registry database may further enhance the adoption rate of such a strategy in clinical practice.

03

Conditions studied

  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors
  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PCI with drug eluting stent (DES) implantation
  2. Age ≥18 years
  3. Ability to sign before any study-specific procedure

Exclusion criteria

Exclusion Criteria:

  1. Planned staged PCI (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop an indication for percutaneous valve intervention can undergo treatment 30 days after full coronary revascularization)
  2. Indication for oral anticoagulation
  3. Peri-procedural complication which affects DAPT regimen based on the operator's opinion (e.g. untreated flow-limiting angiographic complication, intraprocedural stent thrombosis, persistent vessel occlusion/no-reflow at the end of the procedure, major side-branch occlusion, puncture-site related or other relevant bleeding)
  4. Treatment for stent thrombosis at qualifying PCI or within 1 year prior to qualifying PCI
  5. Active bleeding requiring medical attention at qualifying PCI
  6. The presence of hemodynamic instability (persistent systolic blood pressure below 90mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and/or use of percutaneous left ventricular assist devices)
  7. less than 1 year
  8. Women of (i.e. fertile, following menarche and until becoming unless permanently sterile)
  9. Planned surgery within the next 3 months
  10. or known allergy against aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel)
  11. Participation in a drug trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
2,788 participants (estimated)

Study arms

  • Experimental
    Intervention

    Algorithm-guided DAPT duration

    Other: Algorithm-guided DAPT duration

  • Active comparator
    Standard

    Standard-of-care DAPT duration

    Other: Standard-of-care DAPT duration

Interventions

  • OtherAlgorithm-guided DAPT duration

    PRECISE-DAPT score ≥25 / PRECISE-HBR Score ≥23 * Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy * Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy PRECISE-DAPT score \<25 / PRECISE-HBR Score \<23: * Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy * Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy * Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)

  • OtherStandard-of-care DAPT duration

    DAPT strategy at the operators´ discretion in accordance with applicable guidelines

06

What researchers measure

Primary outcomes

  1. Net adverse clinical events (NACE)

    All-cause death, spontaneous myocardial infarction, definite stent thrombosis, stroke or non-access site related BARC 2, 3 or 5 bleeding

    Time frame: 1 year

Secondary outcomes

  1. Major adverse cardiovascular events (MACE)

    Cardiovascular death, spontaneous myocardial infarction, definite stent thrombosis or stroke

    Time frame: 1 year

  2. Major or clinically relevant non-major bleeding

    Non-access site related Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding

    Time frame: 1 year

  3. Major bleeding

    Non-access site related Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding

    Time frame: 1 year

  4. Any non-access site related Bleeding Academic Research Consortium (BARC) bleeding

    Time frame: 1 year

  5. All-cause death

    Time frame: 1 year

  6. Cardiovascular death

    Time frame: 1 year

  7. Myocardial infarction

    Time frame: 1 year

  8. Spontaneous myocardial infarction

    Time frame: 1 year

  9. Target lesion failure

    Cardiac death, target-vessel myocardial infarction or target lesion revascularization

    Time frame: 1 year

  10. Target vessel revascularization

    Time frame: 1 year

  11. Target vessel myocardial infarction

    Time frame: 1 year

  12. Target lesion revascularization

    Time frame: 1 year

  13. Non-target vessel revascularization

    Time frame: 1 year

  14. Any revascularization

    Time frame: 1 year

  15. Definite stent thrombosis

    Time frame: 1 year

  16. Stroke

    Time frame: 1 year

  17. Transient ischemic attack

    Time frame: 1 year

  18. Adherence to DAPT

    According to the TAILOR-DAPT modified Non-adherence Academic Research Consortium (NARC) classification

    Time frame: 1 year

  19. Adherence to DAPT

    According to the traditional classification (Adherent≥80% of the time from randomization to intended DAPT cessation date)

    Time frame: 1 year

Other outcomes

  1. Net adverse clinical events (NACE)

    All-cause death, spontaneous myocardial infarction, definite stent thrombosis, stroke or Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding

    Time frame: 24 months

07

Study locations

4 of 4 sites recruiting
  • University Clinical Center of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
    Recruiting
    • Bojan Stanetic, MD, PhD · Contactbojan.stanetic@gmail.com · +387 51 342-100
    • Bojan Stanetic, MD, PhD · Principal investigator
  • UOC Cardiologia San Giovanni Addolorata Hospital
    Roma, 00184, Italy
    Recruiting
  • Kardiologie Spitalzentrum Biel
    Biel/Bienne, Canton of Bern 2501, Switzerland
    Recruiting
  • Department of Cardiology, Bern University Hospital
    Bern, 3010, Switzerland
    Recruiting
    • Miklos Rohla, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2029, 78 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 78 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2027 → Dec 2029 and completion Dec 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 17, 2023
StartActual
Jun 27, 2023
Primary completionEst.
Dec 2029was Dec 2027
CompletionEst.
Dec 2030was Dec 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Kardiologie Spitalzentrum Biel · Biel/Bienne, Switzerland
Nov 3, 2026
Primary completion
Dec 2027→Dec 2029
Nov 3, 2026
Study completion
Dec 2028→Dec 2030
Nov 3, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionNet adverse clinical events (NACE): how it is measured was reworded
Nov 3, 2026
Secondary outcomes
1 edited, 2 description edited
What changed in the outcomes
  • EditedAny non-access site related Bleeding Academic Research Consortium (BARC) bleedingTime frame: 1 year
  • DescriptionMajor bleeding: how it is measured was reworded
  • DescriptionMajor or clinically relevant non-major bleeding: how it is measured was reworded
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    1 site added
    Show site
    • Kardiologie Spitalzentrum Biel · Biel/Bienne, Switzerland
    Primary completion Dec 2027→Dec 2029
    Study completion Dec 2028→Dec 2030
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNet adverse clinical events (NACE): how it is measured was reworded
    Secondary outcomes 1 edited, 2 description edited
    What changed in the outcomes
    • EditedAny non-access site related Bleeding Academic Research Consortium (BARC) bleedingTime frame: 1 year
    • DescriptionMajor bleeding: how it is measured was reworded
    • DescriptionMajor or clinically relevant non-major bleeding: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05732701
Responsible party
Sponsor
First posted
Feb 17, 2023
Start date
Jun 27, 2023
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Lorenz Räber, MD, PhD
Contact
Lorenz.raeber@insel.ch
+41 31 632 09 29
Miklos Rohla, MD, PhD
Contact
miklos.rohla@insel.ch
+41 31 632 21 11
Lorenz Räber, MD, PhD
study chair · Department of Cardiology, Bern University Hospital, Bern, Switzerland
Miklos Rohla, MD, PhD
principal investigator · Department of Cardiology, Bern University Hospital, Bern, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion